Literature DB >> 28722023

Potential Involvement of Impaired BKCa Channel Function in Sensory Defensiveness and Some Behavioral Disturbances Induced by Unfamiliar Environment in a Mouse Model of Fragile X Syndrome.

Maria Isabel Carreno-Munoz1,2,3, Fabienne Martins1,2, Maria Carmen Medrano1,2, Elisabetta Aloisi1,2, Susanna Pietropaolo4,5, Corentin Dechaud1,2, Enejda Subashi1,2, Guillaume Bony1,2, Melanie Ginger1,2, Abdelmalik Moujahid3, Andreas Frick1,2, Xavier Leinekugel1,2.   

Abstract

In fragile X syndrome (FXS), sensory hypersensitivity and impaired habituation is thought to result in attention overload and various behavioral abnormalities in reaction to the excessive and remanent salience of environment features that would normally be ignored. This phenomenon, termed sensory defensiveness, has been proposed as the potential cause of hyperactivity, hyperarousal, and negative reactions to changes in routine that are often deleterious for FXS patients. However, the lack of tools for manipulating sensory hypersensitivity has not allowed the experimental testing required to evaluate the relevance of this hypothesis. Recent work has shown that BMS-204352, a BKCa channel agonist, was efficient to reverse cortical hyperexcitability and related sensory hypersensitivity in the Fmr1-KO mouse model of FXS. In the present study, we report that exposing Fmr1-KO mice to novel or unfamiliar environments resulted in multiple behavioral perturbations, such as hyperactivity, impaired nest building and excessive grooming of the back. Reversing sensory hypersensitivity with the BKCa channel agonist BMS-204352 prevented these behavioral abnormalities in Fmr1-KO mice. These results are in support of the sensory defensiveness hypothesis, and confirm BKCa as a potentially relevant molecular target for the development of drug medication against FXS/ASD.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28722023      PMCID: PMC5770751          DOI: 10.1038/npp.2017.149

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  54 in total

1.  Relationship between cerebral pharmacokinetics and anxiolytic activity of diazepam and its active metabolites after a single intra-peritoneal administration of diazepam in mice.

Authors:  E Dailly; M Hascoët; M C Colombel; P Jolliet; M Bourin
Journal:  Hum Psychopharmacol       Date:  2002-07       Impact factor: 1.672

2.  The GABA(A) receptor agonist THIP ameliorates specific behavioral deficits in the mouse model of fragile X syndrome.

Authors:  Jose Luis Olmos-Serrano; Joshua G Corbin; Mark P Burns
Journal:  Dev Neurosci       Date:  2011-11-08       Impact factor: 2.984

Review 3.  Toward fulfilling the promise of molecular medicine in fragile X syndrome.

Authors:  Dilja D Krueger; Mark F Bear
Journal:  Annu Rev Med       Date:  2011       Impact factor: 13.739

4.  Alterations in the auditory startle response in Fmr1 targeted mutant mouse models of fragile X syndrome.

Authors:  Darci M Nielsen; William J Derber; Danielle A McClellan; Linda S Crnic
Journal:  Brain Res       Date:  2002-02-08       Impact factor: 3.252

5.  Matrix metalloproteinase-9 deletion rescues auditory evoked potential habituation deficit in a mouse model of Fragile X Syndrome.

Authors:  Jonathan W Lovelace; Teresa H Wen; Sarah Reinhard; Mike S Hsu; Harpreet Sidhu; Iryna M Ethell; Devin K Binder; Khaleel A Razak
Journal:  Neurobiol Dis       Date:  2016-02-02       Impact factor: 5.996

6.  (Over)correction of FMR1 deficiency with YAC transgenics: behavioral and physical features.

Authors:  A M Peier; K L McIlwain; A Kenneson; S T Warren; R Paylor; D L Nelson
Journal:  Hum Mol Genet       Date:  2000-05-01       Impact factor: 6.150

7.  Genetic-background modulation of core and variable autistic-like symptoms in Fmr1 knock-out mice.

Authors:  Susanna Pietropaolo; Aurélie Guilleminot; Benoît Martin; Francesca R D'Amato; Wim E Crusio
Journal:  PLoS One       Date:  2011-02-22       Impact factor: 3.240

8.  Evidence for social anxiety and impaired social cognition in a mouse model of fragile X syndrome.

Authors:  Caitlyn H McNaughton; Jisook Moon; Myla S Strawderman; Kenneth N Maclean; Jeffrey Evans; Barbara J Strupp
Journal:  Behav Neurosci       Date:  2008-04       Impact factor: 1.912

9.  Hyperactivity, perseveration and increased responding during attentional rule acquisition in the Fragile X mouse model.

Authors:  Ioannis Kramvis; Huibert D Mansvelder; Maarten Loos; Rhiannon Meredith
Journal:  Front Behav Neurosci       Date:  2013-11-21       Impact factor: 3.558

10.  Enriched environment promotes behavioral and morphological recovery in a mouse model for the fragile X syndrome.

Authors:  Leonardo Restivo; Francesca Ferrari; Enrica Passino; Carmelo Sgobio; Jörg Bock; Ben A Oostra; Claudia Bagni; Martine Ammassari-Teule
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-02       Impact factor: 11.205

View more
  9 in total

1.  (S)-5-(2'-Fluorophenyl)-N,N-dimethyl-1,2,3,4-tetrahydronaphthalen-2-amine, a Serotonin Receptor Modulator, Possesses Anticonvulsant, Prosocial, and Anxiolytic-like Properties in an Fmr1 Knockout Mouse Model of Fragile X Syndrome and Autism Spectrum Disorder.

Authors:  Jessica L Armstrong; Austen B Casey; Tanishka S Saraf; Munmun Mukherjee; Raymond G Booth; Clinton E Canal
Journal:  ACS Pharmacol Transl Sci       Date:  2020-02-21

Review 2.  FMR1 and Autism, an Intriguing Connection Revisited.

Authors:  William Fyke; Milen Velinov
Journal:  Genes (Basel)       Date:  2021-08-06       Impact factor: 4.096

Review 3.  Channelopathies in fragile X syndrome.

Authors:  Pan-Yue Deng; Vitaly A Klyachko
Journal:  Nat Rev Neurosci       Date:  2021-04-07       Impact factor: 34.870

4.  Early Retinal Defects in Fmr1-/y Mice: Toward a Critical Role of Visual Dys-Sensitivity in the Fragile X Syndrome Phenotype?

Authors:  Olivier Perche; Chloé Felgerolle; Maryvonne Ardourel; Audrey Bazinet; Arnaud Pâris; Rafaëlle Rossignol; Géraldine Meyer-Dilhet; Anne-Laure Mausset-Bonnefont; Betty Hébert; David Laurenceau; Céline Montécot-Dubourg; Arnaud Menuet; Jean-Charles Bizot; Jacques Pichon; Isabelle Ranchon-Cole; Sylvain Briault
Journal:  Front Cell Neurosci       Date:  2018-04-06       Impact factor: 5.505

5.  Gamma power abnormalities in a Fmr1-targeted transgenic rat model of fragile X syndrome.

Authors:  Naoki Kozono; Ai Okamura; Sokichi Honda; Mitsuyuki Matsumoto; Takuma Mihara
Journal:  Sci Rep       Date:  2020-11-02       Impact factor: 4.379

6.  Large-conductance calcium-activated potassium channel haploinsufficiency leads to sensory deficits in the visual system: a case report.

Authors:  Olivier Perche; Fabien Lesne; Alain Patat; Susanne Raab; Roy Twyman; Robert H Ring; Sylvain Briault
Journal:  J Med Case Rep       Date:  2022-05-05

7.  CRL4 antagonizes SCFFbxo7-mediated turnover of cereblon and BK channel to regulate learning and memory.

Authors:  Tianyu Song; Shenghui Liang; Jiye Liu; Tingyue Zhang; Yifei Yin; Chenlu Geng; Shaobing Gao; Yan Feng; Hao Xu; Dongqing Guo; Amanda Roberts; Yuchun Gu; Yong Cang
Journal:  PLoS Genet       Date:  2018-01-25       Impact factor: 5.917

Review 8.  Physiological Roles and Therapeutic Potential of Ca2+ Activated Potassium Channels in the Nervous System.

Authors:  Aravind S Kshatri; Alberto Gonzalez-Hernandez; Teresa Giraldez
Journal:  Front Mol Neurosci       Date:  2018-07-30       Impact factor: 5.639

9.  Hyperexcitability and Homeostasis in Fragile X Syndrome.

Authors:  Xiaopeng Liu; Vipendra Kumar; Nien-Pei Tsai; Benjamin D Auerbach
Journal:  Front Mol Neurosci       Date:  2022-01-06       Impact factor: 5.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.